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The human cytomegalovirus (CMV) is one of the common viral infections 
worldwide that represent a major causes of congenital infections. To 
determine the seroprevalence of CMV in women with bad obstetric history 
and sociodemographic characteristics that may influence the seropositivity, 
a case control descriptive prospective study  was conducted in Kirkuk, Iraq. 
A 838 women with age range from 14 to 48 were included in the study. Of 
the total, 547 women were with bad obstetric history(BOH) and 291 women 
with normal previous pregnancy as control group. All the serum samples 
collected from the study and control groups were tested for CMV IgM and 
IgG antibodies by ELISA kits. CMV IgM seroprevalence was higher in 
women with BOH. CMV IgG seroprevalence was with no significant  
difference between BOH and control. CMV IgG seroprevalence 
significantly influenced by age, education, smoking, and family size. 
However, CMV IgM seroprevalence significantly associated with 
pregnancy, residence, and animal exposure. Odd ratio confirmed the 
association between CMV IgG and age, crowding index, residence, 
smoking, and number of abortion in women with BOH.  In addition, current 
CMV infection significantly associated with residence in women with BOH. 
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1. INTRODUCTION 
The human cytomegalovirus (HCMV) is the most common congenital viral infection worldwide and 
may be asymptomatic forms (90% of cases) to severe fetal damage and, in rare cases, death due to abortion 
[1]. Cytomegalovirus (CMV) infection during pregnancy is far more complex than other infections, due to 
the ability of the virus to be frequently reactivated during the child bearing age and be transmitted to the fetus 
inspite of maternal immunity [2]. HCMV infection was a complex phenomenon since the virus act as an 
immune modulator through elaborating an array of immune evasion strategies to avoid elimination from the 
host, and its viral proteins an involved in the regulation of cellular gene expression and induction of pro-
inflammatory cytokine [3] or induction of autoimmune status [4]. 
There are many confounding studies about the association between CMV infection and pregnancy 
loss; the studies showed that HCMV can result in abortion or stillbirth [5],[6].  Cytomegalovirus is frequently 
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causative agent of prenatal and perinatal infection and may lead to important complications on pregnancy [7]. 
The seropositivity of  CMV varies widely around the  world [8]. A review [9] of 40 globally reported studies 
on CMV seroepidemiology indicated a range of seropositivity from 30.4% for Ireland [10] to 98.9% for 
Turkey [11]  in pregnant/ and or child bearing age women. In addition, seroprevalence rate range was from 
14.2% for Iran [12] to 91.05% for India [13]  in women with bad obstetric history.  
In Arab countries , we review 21 reported studies [9], which indicated a seroprevalence rate range  
from 77.8% for Babylon, Iraq [14] to 88% for Jordan [15] in pregnant women. While the range of 
seroprevalence was from 4.8% for Baghdad, Iraq [16] to 95% for Jordan [15] in women with bad obstetric 
history.   
In Iraq, the CMV seroepidemiology ranged from 8.02% (un acceptable low rate) to 90.4%, a wide 
range of seroprevalence. In addition, the sample size of study population was from 60-230, thus this study 
conducted on a large size study population to clarify the seroepidemiology of CMV in women with BOH [9].   
The aim of the present study is to determine the seroprevalence of CMV in women with bad obstetric history 
and sociodemographic characteristics that may influence the seropositivity. 
 
 
2. PATIENTS AND METHODS 
 
Study Design and Settings:  
The study design is a Descriptive Case Control Study and was performed in Kirkuk General 
Hospital. The study proposal was approved by Tikrit University College of Science ethical committee and 
Kirkuk Health Authority Research Committee. Informed consent taken from each women included in the 
study. 
 
Study Population:  
The study population is women with childbearing age. Study population was recruited from Kirkuk 
General Hospital.  A 838 women with age range from 14 to 48 were included in the study. Of the total, 547 
women were with bad obstetric history (BOH) and 291 women with normal previous pregnancy as control 
group. The demographic information of these groups are shown in Table 1. For serological analysis, 5-10 mL 
of venous blood was collected in a sterile container with strict aseptic precautions from each study subject. 
The serum was separated and stored in numbered aliquots at -20 oC till assayed. All the serum samples 
collected from the study and control groups were tested for CMV IgM and IgG antibodies by commercially- 
available (ELISA) kits. The results read by a Microwell reader and compared in a parallel manner with 
controls; optical density read at 450 nm on an ELISA reader. 
 
Collection of data 
All recruited women were subject for clinical examination and laboratory investigations were  
carried out for the study subjects to exclude other causes of foetal wastage, such as hypertension, diabetes 
mellitus, syphilis, Rh (rhesus) incompatibility, physical causes of abortion, and consanguinity. Subjects with 
known causes of foetal wastage were  excluded from the study. All of them were interviewed to ascertain 
age, medical and obstetric information. 
 
Determination of CMV IgM and IgG: 
ELISA was used for determination of IgM and IgG for CMV and the test was performed according 
to manufacturer instructions. The kit purchased from BioCheck, Inc, 323 Vintage Park Dr, Foster City, CA 
94404.  
 
Statistical Analysis: 
The proportion and the mean value were computed in appropriate situations. To find out any 
association between categorical data, Chi square test was  employed using the SPSS (Version 16). If the 
sample size in BOH group not reach the targeted number Power Analysis were performed to determine the 
accuracy of findings. The study finding data were presented as frequency  ± SD and 95% Confidence 
Interval. The determinants for HSV 2 infection is determined by calculation of Odd Ratio. Chi square used to 
determine the significance of differences between the groups.   
 
3. RESULTS AND DISCUSSION 
The overall CMV seroprevalence in our study population was 92.1% and an it was with no 
significant difference between women with BOH (91.2%) and women with normal pregnancy (93.8%) 
outcomes (X2=1.7, P>0.05). Furthermore, current CMV infection was lower in women with BOH (3.8%) 
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than that in women with normal pregnancy (4.5%) outcomes (X2=0.19, P>0.05), Table 2.  There were a 
significant differences in CMV IgG seroprevalence between pregnant and non pregnant women in BOH       
(X2=6.82, P=0.007) and control (X2=6.76, P=0.008) groups. However, such pattern was demonstrated in 
control group for CMV IgM (X2=14.64, P=0.000) seroprevalence, Table 2. 
There was a non significant difference (X2=0.6, P>0.05) in CMV IgG seroprevalence between 
pregnant (92.8%) and non- pregnant (91.4%) women. In addition, current infection as demonstrated in IgM 
positivity was significantly higher (X2=6.85, P=0.007) in pregnant women (5.8%) as compared to non-
pregnant (2.2%) women. Table 3. 
Age significant seroprevalence variation was demonstrated for CMV IgG in both BOH (X2=9.21, 
P=0.027) and control (X2=20.5, P=0.000).  In BOH group, CMV IgG seropositivity was 95.6%  in women 
with age of < 20 years, then declined in women with age. While in control group  seropositivity was 100% in 
women with age of <20 and then decline in women with age of 20-29 years, but subsequently increased to 
reach 100% in women with age of 40 -48 years.  CMV IgM seroprevalence was lowest in women with 30-39 
years age (3.3%), and highest (4.6%) in women with age of 14 – 29 years. However, in control CMV IgM 
was detected in women with 20-29 years of age (10.3%). In addition, there was a significant (P=0.03) higher 
CMV IgM seroprevalence (10.3%) in control as compared to women with BOH (4.6%) in the age of 20 to 29 
years. While in the age group 30 – 39 years, CMV IgM was significantly higher (P=0.007) in women with 
BOH (3.3%) as that in control (0%), Table 4. 
CMV IgG seroprevalence was with significant differences between control and women with BOH. 
The seroprevalence rate was significantly (P=0.007) lower in control (86.6%) as compared to women with 
BOH (94.6%) with age of 20-29 years, while with reverse pattern for the age groups of 30-39 (control 
,98.9%; BOH, 87.4%, p=0.002)  and 40-48 years (control ,100%; BOH, 87.4%, p=0.038). Table 4. 
The CMV IgM seroprevalence was higher in women with age of < 30 years (4.2%) as compared to 
those >  30 years (3.4%), but the difference not reach a significant level (X2=0.22, P=>0.05). While in the 
control group the rate also higher in women <30 years (7.5%) as compared to those >30 years (0%,  X2=9.28, 
P=0.002), Table 5.  OR also not confirmed a significant association between age of <30 years and CMV IgM 
(OR=0.81,P>0.05), Table 6. The CMV IgG seroprevalence was significantly (X2=9.17, P=0.003) higher in 
BOH women of <30 years (94.7%) than those of >30 years (87.4%). While in the control group, it was 
significantly higher (X2=9.75, P=0.002) in women with age >30 years (99.2%), Table 5. OR  confirmed the 
association between age of <30 years and CMV IgG (OR=2.594, P=0.003) seropositivity, while CMV IgM 
seropositivity was associated with age of <30 years (OR=2.38,P=0.028) when data of BOH and control 
collected together. In women with age of >30 years, there were a significant differences between BOH and 
control group in CMV IgM seroprevalence (X2=4.15, P=0.042) and  CMV IgG seroprevalence (X2=13.8, 
P=0.000), Tables 5 & 6.  
Women living in rural areas demonstrate 92% seropositivity for CMV IgG, while in urban area the 
seropositivity was 90.9%, with no significant difference (X2=0.169,P>0.05). However, current infection was 
significantly (X2=10.18, P=0.000) higher  in women from urban (5.6%) areas as it was not detected in 
women from rural (0%) areas, Table 7. OR confirmed the association between residence and CMV 
seroprevalence for IgM (OR=29.71,P=0.01), but not for IgG (OR=1.146, P>0.05), Table 8. 
CMV IgG seropositivity was about the  same (X2=0.001, P>0.05) in working women (91.1%) as 
compared to housewife (91.2%) women. However, CMV IgM (current infection) was 4.2% in housewife and 
not detected in any working women (0%). OR not confirm any significant association between occupation 
and both IgM (OR=0.246,P>0.05) and IgG (OR=0.985,P >0.05), Tables 7 & 8.  
Education levels significantly influenced CMV seroprevalence for IgG (X2=4.33, P=0.037) in our 
study population, but not IgM (X2=0.03, P>0.05) . OR confirmed such association for IgG (OR=2.003, 
=0.026), but not for IgM (OR=0.503, P>0.05), Tables 7 & 8. Small size (crowding index <3) families were 
with higher seroprevalence for CMV IgM (4.2%), but not reach significant (X2=0.16, P>0.05). However,  
CMV IgG was significantly (X2=73.4, P=0.000) lower (75.2%) in families of >3 crowding index.  OR  
confirmed significant association between family size and IgG seropositivity (OR=17.713, P=0.0001), but 
not for IgM (X2=0.711, P>0.05), Tables 7 & 8. 
CMV IgM seropositivity rate was about the same in smoker (4%) and non- smoker (3.6%) women 
with BOH (X2=0.04, P>0.05). However, CMV IgG seropositivity was significantly (X2=8.93, P=0.003) 
higher (94.2%) in smoker than non-smoker (86.8%) women, Table 7. OR confirmed the association between 
smoking and CMV IgG seropositivity (X2=2.461, P=0.002), but not for current infection (X2=0.912, P>0.05), 
Table 8. 
CMV IgG seroprevalence was higher in BOH women with haemoglobin of <11 g/dl (92.1%) than 
those with >11 g/dl (90.9%), but the difference was not significant (X2=0.06, P>0.05). OR not confirmed an 
association between haemoglobin level in women with BOH and  both CMV IgM (OR=0.813, P>0.05) and 
IgG (OR=0.863, P>0.05). BOH women exposed to animal was with higher (92.8%) non significant (X2=0.91, 
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P>0.05) CMV IgG seroprevalence than non exposed (90.4%). However, CMV IgM was significantly 
(X2=8.99, P=0.001) higher (5.7%) in non exposed BOH women (0.5%). OR not confirmed association 
between animal exposure and both CMV IgG (OR=1.37, P>0.05) and IgM (OR=0.086, P>0.05) in women 
with BOH, Tables 7 & 8. 
There was a significant (X2=6.1, P=0.01) differences in CMV IgG seroprevalence in women with 
repeated abortion of >3 (89.5%) and those below (97.4%), while IgM not show a significant difference 
(X2=0.63, P>0.05). OR confirmed an association between number of abortion and CMV IgG seropositivity 
(OR=4.391, P=0.01), Tables 7 & 8. Women with history of congenital anomalies were with higher (95.9%; 
X2=1.48, P>0.05) CMV IgG seroprevalence than those without (90.8%). In addition, CMV IgM 
seropositivity was 4.1% in women with history of congenital anomalies and 3.8% in those without 
(X2=0.009, P>0.05). OR not confirmed an association between congenital anomalies and CMV IgG 
(OR=0.418, P>0.05) and CMV IgM  (X2=0.932, P>0.05), Tables 7 & 8. 
 
Table 1. Study population 
Group Number Mean age ± SD in years 
Women with bad  
obstetric history 
Pregnant  292 28.35 ± 7.25 
Non pregnant 255 28.24 ± 6.81 
Total  547  
Women with normal 
pregnancy 
Pregnant  140 27.40 ± 6.24 
Non pregnant  151 28.06 ± 10.51 
Total  291  
Grand total 838 28.42 ± 7.72  
P value ANOVA                                      NS 
 
Table 2. Cytomegalovirus  seroprevalence in women with bad obstetric history 
Group [Number] Number  positive [Percent] IgM IgG 
Bad obstetric history Pregnant           [292] 12 [4.1] 275 [94.2] 
Non- pregnant [255] 9 [3.5] 224 [87.8] 
X2 0.124 6.82 
P value NS 0.007 
Total                   [547] 21 [3.8] 499 [91.2] 
Normal pregnancy Pregnant            [140] 13[9.3] 126 [90] 
Non- pregnant  [151] 0 [0] 147 [97.4] 
X2 14.64 6.76 
P value 0.000 0.008 
Total                   [291] 13 [4.5] 273 [93.8] 
Grand total                                           [838]             34 [4.1] 772 [92.1] 
X2                 BOH  versus  Normal Pregnancy 0.19 1.76 
P  value  BOH versus  Normal Pregnancy NS NS 
 
Table 3. Cytomegalovirus  seroprevalence  in pregnant  compared to non-pregnant women 
Group  [Number] Number  positive  [Percent] IgM IgG 
Pregnant                   [432] 25 [5.8] 401 [92.8] 
Non- pregnant         [406] 9 [2.2]  371 [91.4] 
X2 6.85 0.60 
P value 0.007 NS 
 
Table 4  .  Comparison of Frequency of Cytomegalovirus   in BOH compared to control agents in 
regard to age 
Age group in 
years 
 
IgM  
Number positive\total [%] 
IgG 
Number positive\total [%] 
Control Patient X2 P value Control Patient X2 P Value 
14 – 19  0\47 
[0] 
1\45 
[4.6] 
0.97 NS 47\47 
[100] 
43\45 
[95.6] 
2.14 NS 
20 – 29 13\126 
[10.3] 
11\240 
[4.6] 
4.43 0.03 109\126 
[86.6] 
227\240 
[94.6] 
7.16 0.007 
30 – 39 0\86 
[0] 
7\214 
[3.3] 
7.3 0.007 85\86 
[98.9] 
187\214 
[87.4] 
9.51 0.002 
40 – 48  0\32 
[0] 
2\48 
[4.2] 
1.37 NS 32\32 
[100] 
42\48 
[87.5] 
4.32 0.038 
X2 17.8 0.88  20.5 9.21  
P value 0.000 NS  0.000 0.027  
ND= Non determinable. 
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Table 5 . Frequency of CMV according to age of <30 and above 
Variable 
Age 
in 
years. 
Total No. 
 
IgM 
Number positive 
[%] 
IgG 
Number positive 
[%] 
Con. Pat Con. Pat. X2 P Con. Pat. X2 P 
CMV 14 -29 173 285 13  
[7.5] 
12 [4.2] 2.28 NS 156 [90.2] 270 [94.7] 3.45 NS 
30-48 118 262 0 
[0] 
9 [3.4] 4.15 0.042 117 [99.2] 229 [87.4] 13.8 0.000 
X2   0.22  9.75 9.17  
P   NS  0.002 0.003  
 
Table  6  Odd ratio of Cytomegalovirus  in regards to age of  women lower than 30 years 
Variable Odd ratio [95% Confidence interval] P value  
CMV  IgM 0.810   [0.335 – 1.953]  NS 
 
 
 
CMV   IgG 
 
2.594   [1.374 – 4.896] 0.003 
 
Table  7  Frequency of HSV 2  IgG and IgM in regard to sociodemographic characteristics 
 
Variable 
 
[Number] 
Number  positive  [Percent] 
IgM IgG 
 
Residence  
Rural [174] 0 [0] 160 [92] 
Urban [373] 21 [5.6] 339 [90.9] 
X 2 10.187 0.169 
P value 0.000 NS 
 
Occupation  
House wife [502] 21 [4.2] 458 [91.2] 
Working    [45] 0 [0] 41 [91.1] 
X 2 1.958 0.001 
P value NS NS 
 
 
 
Education 
Uneducated  [142]          5 [3.5] 123 [86.6] 
 Educated      [405] 15 [3.7] 376 [92.8] 
X 2 0.03 4.33 
P value NS 0.037 
 
Crowding  Index 
≤    3  [382] 16 [4.2] 375 [98.2] 
3.1 – 8 [165] 5 [3] 124 [75.2] 
X 2 0.16 73.4 
P value NS 0.000 
 
Smoking 
Present        [327] 13 [4] 308 [94.2] 
No smoking [220] 8 [3.6] 191 [86.8] 
X 2 0.04 8.93 
P value NS 0.003 
 
Haemoglobin 
< 11                [151] 5 [3.3] 139 [92.1] 
11 -19             [396] 16 [4] 360 [90.9] 
X 2 0.04 0.06 
P value NS NS 
 
Animal exposure 
Present        [194] 1 [0.5] 180 [92.8] 
Absent         [353] 20 [5.7] 319 [90.4] 
X 2 8.99 0.91 
P value 0.001 NS 
 
Abortion number 
 1 – 2 [116] 3 [2.6] 113 [97.4] 
3 – 8  [431] 18 [4.2] 386 [89.5] 
X2 0.63 6.1 
P value NS 0.01 
 
Congenital anomalies 
Absent [498] 19 [3.8] 452 [90.8] 
Present  [49] 2 [4.1] 47 [95.9] 
X2 0.009 1.48 
P value NS NS 
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Table   8  Association of CMV seropositivity  with sociodemographic characteristics using Bivariate 
analysis 
Variable Odd ratio [95% Confidence interval] P value 
Occupation  
[Housewife versus  Official] 
IgM 0.246 [0.015 – 4.13] NS 
IgG 0.985 [0.337 – 2.87] NS 
Crowding Index  
[ < 3 versus >3] 
IgM 0.711 [0.256 – 1.974] NS 
IgG 17.713 [7.748 – 40.495] <0.0001 
Education [Educated versus Uneducated] IgM  0.503 [0.115 – 2.198] NS 
IgG 2.003 [1.085 – 3.698] 0.026 
Residence  
[Rural versus Urban] 
IgM 29.71 [1.788 – 493.858] 0.01 
IgG 0.872 [0.455 – 1.671] NS 
Smoking IgM 0.912 [0.371 – 2.237] NS 
IgG 2.461 [1.343 – 4.512] 0.002 
Haemoglobin IgM 0.813 [0.293 – 2.261] NS 
IgG 0.863 [ 0.436 – 1.707] NS 
Animal exposure IgM 0.086 [0.012 – 0.648] NS 
IgG 1.370 [0.716 – 2.622] NS 
Abortion number IgM 0.609 [0.176 – 2.105] NS 
IgG 4.391 [1.339 – 14.396] 0.01 
Congenital anomalies  IgM 0.932 [0.211 – 4.126] NS 
IgG 0.418 [0.098 – 1.777] NS 
 
Discussion 
The present study shows a high CMV IgG overall seroprevalence (92.1%), with no significant 
differences between rate in women with BOH and that with normal pregnancy. Thus the susceptibility rate in 
our study population was 7.9%, which was higher to that reported recently for  Turkey [11],[17]-[22], Nigeria 
[23],[24], Brazil [25], Iran [26],[27], Bangladesh [28], Korea [29], and Cuba [30].  However, our study 
susceptibility was lower than that reported for France [31], Nepal [32], India [13],[33],[34], Switzerland [35], 
Croatia [36], Malaysia [37], Iran [12],[38], Poland [39], Ireland [10], Russia [40], Taiwan [41], Germany 
[42], Azerbaijan [43], Bangladesh [44], and Brazil [45]. In comparison to Arab countries, this study 
susceptibility rate was lower to that reported for Egypt [46], Sudan [47], Syria [48], and Jordan [15], but 
similar to that reported for Saudi Arabia [49], and higher to rate in Qatar [50], Sudan [51], and Tunisia [52]. 
The comparison with Iraqi studies, this study was with higher rate to that reported for Kirkuk [53], 
but was lower to that reported for  Baghdad , Waset, Al-Anbar, Al-Hila, Thi Qar, Kirkuk, Diwaniya, and 
Babylon [54],[14],[15],[55]-[61]. However, the mostly deviated rates were that reported for Kirkuk [59], 
Baghdad [16] and Thi Qar [62], which they reported a very low seroprevalence rate of CMV. 
In the present study and in that  reported globally show a high seroprevalence of CMV IgG 
antibodies, however, this preconceptional immunity against CMV provide incomplete protection against 
intrauterine transmission, and adverse outcomes can occur in infected children born to women who were 
seropositive prior to pregnancy [63]-[67]. Transplacental transmission of CMV in women with preexisting 
seroimmunity may be a secondary to virus reactivation [68] or to infection with a new different CMV strain 
(reinfection) [69] during pregnancy.  
Previous immunization with CMV is not perfectly protective against either reinfection or vertical 
transmission of infection from mother to fetus [20],[23]. In a recent study, approximately one third of the 
study seroimmune women were noted to have CMV reinfection during follow up [69].  A recent review of   
the literature indicated that the incidence of congenital CMV infection increases with increasing maternal 
CMV seroprevalence [68]. The positive correlation between higher maternal seroprevalence and high birth 
prevalence may seem paradoxical because this suggests that a smaller number of pregnant women are at risk 
for primary infection. However, in a high seroprevalence population, the number of pregnancies at risk for 
reactivation is also increased. In addition, the high seroprevalence may be due to a higher prevalence of risky 
behaviors in the population. In a high seroprevalence population, a pregnant woman has a higher likelihood 
of exposure to CMV-infected people. Thus, in a high risk population, seropositive women have a higher risk 
of reactivation and seronegative women have a higher risk of primary infection [70]. Preventive measures 
should be taken to decrease perinatal mortality and morbidity related to CMV infection and to ensure that 
women are not infected with CMV during pregnancy. Pregnant women should be consulted and encouraged 
to implement these preventive measures. Routine nationwide screenings for this condition should be 
considered, although serious cost effectiveness issues need to be evaluated before the implementation of such 
screenings.  
In Kirkuk, CMV seroprevalence is as high as 92.1%. Routine CMV screening in such a population 
is unnecessary, but there are exceptions. Pregnant women who had contact with a patient with a proven acute 
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CMV infection, as well as patients with upper respiratory system infection-like symptoms, hepatomegaly, 
elevated liver enzymes, lymphadenopathy and immunocompromised statuses should all receive screening 
[20]. Thus, a routine screening test is usually justified only for conditions with an expected high rate of 
infection, conditions that have a proven mode of prevention and conditions where the screening method is 
safe and inexpensive [53]. At this time, routine screening for CMV is not recommended given the high 
seropositivity prevalence. Because there is no consistently effective treatment for congenital CMV infection 
available, the testing is clinically useless and expensive. However, Nigro et al. [71] recently reported 
promising results concerning passive immunization against congenital CMV infection.  
In the current study there was a significant (X2=6.82, P=0.007) difference in CMV seroprevalence 
between pregnant (94.2%) and non pregnant (87.8%) women with bad obstetric history. In addition, there 
was a significant difference between pregnant (90%) and non pregnant (97.4%) women with previous normal 
pregnancy (X2=6.76, P=0.008). Furthermore, CMV-IgG seroprevalence was not significantly (X2=0.6, 
P>0.05) different  in non pregnant (91.4%) from that in pregnant (92.8%) women.  
CMV-IgG seroprevalence among our study population women ranged from 87.4% to 95.6%  across 
age groups and shows a  significant trends with age (X2=9.21, P=0.027). However, there was a significant 
(X2=4.32-9.51, P=0.038-0.002) differences in seroprevalence between women with BOH and control among 
the age groups of 20-29,30-39,qnd 40-48. In addition, the women in the age group 30 and above years  old 
had lower prevalence CMV-IgG (87.4%, 229/262) as compared to women in the age of <30 years 
(94.7%,270/285). This difference was significant as confirmed by OR calculation (OR=2.594, P=0.003). This 
trend was not consistent to a recently reported study in Kirkuk in which the rate was higher in women with 
age of >30 years [53]. The difference between the two studies was due to that the present study included only 
BOH group, while the recently reported study include BOH and control collected together. The CMV 
transmission variation in different age groups could be due to fact that as the women  interaction and 
encounter with the risk factors tend to increase or decrease according to age [72] and social characters. Our 
finding was in consistent to that reported for other geographical areas [20],[47],[72],[73],[74]. 
Seroprevalence for CMV  between the age of 15 to 19 years was too high (95.6%). This high seroprevalence 
could be attributed to the widely practice of breastfeeding during infancy [75]. Breastfeeding is a common 
practice in Iraq and it is known to be a significant source of CMV transmission to children and plays an 
important role in the epidemiology of  CMV infection  as the virus is reactivated during lactation in nearly 
every seropositive mother [76]. In addition, close contacts and crowdness in the primary and secondary 
schools could contribute to such increase in CMV seroprevalence [77]. The antibody prevalence reduced 
(94.6%) in the age group of 20 -29 years. This finding was not agreed to that reported for USA, in which 
seroprevalence  increased steadily with age [78], but agreed with that reported for Portugal [74]. Studies with 
similar age groups conducted in other countries, such as USA, Japan, France, England, Poland, and Russia, 
describe seroprevalences ranging between 51.5% and 78% [40],[79]-[84]. 
The seroprevalence of women with CMV-IgG gradually reduced  in the two oldest age groups, with 
values of  87.4% and  87.5%, suggesting that sexual transmission was an important route of transmission of 
the virus in the population [85]. Another recognized source of adult CMV infection are children. CMV 
infected children shed virus in saliva and urine for years, providing an opportunity for continued spread to 
other children and susceptible adults (close relative, teachers) [86],[87]. 
Nevertheless, it should be noted that in our study, 7.2 % of the pregnant women were susceptible to 
CMV, a finding that was not significantly different from that recently reported (6.5%) for Kirkuk [53]. In 
addition,  5.8%  of  pregnant women was with current infection,  which let us to conclude that there is a 
considerable risk for congenital infection due to maternal primary CMV infection, which leads to fetal 
infection in approximately 40% of cases (6% congenital infection in our cohort) [88]. However, this rate of 
current infection was lower to that reported for Kirkuk (9.6%) recently, which indicating a reduction in 
primary CMV infection. In this risk group (women with primary CMV), we must apply the approaches to 
prevent congenital CMV infections, which include improved hygiene behavior, of seronegative women, 
administration of hyperimmune globulin to pregnant women with primary infection or pregnant women with 
previous infection who demonstrated CMV antibody titers or low IgG avidity [89].  
Child-to-mother transmission of CMV during pregnancy in seronegative women could be controlled 
or prevented through simple hygiene such as frequent hand washing, wearing gloves for specific childcare 
tasks and avoiding intimate contact with their child such as sharing utensils, food or towels, and kissing on or 
near mouth [90]-[92].                
Despite advances in the diagnosis of maternal-fetal CMV infection and approaches to prevent 
congenital CMV, an effective prenatal therapy is unavailable. A prospective, non-randomised study of 
pregnant women who acquired CMV infection during pregnancy and who received passive  immunisation 
with CMV HIG, showed that this therapy was associated with a significantly reduced risk of congenital CMV 
disease and infection and had no adverse effects [89],[93],[94]. Recent case reports supported safe 
                ISSN: 2252-8806 
IJPHS  Vol. 3, No. 1,  March 2014 :  29 – 42 
36
administration of oral ganciclovir to mothers of CMV-infected fetuses, with no teratogenic side effects when 
given in the early stages of pregnancy [89],[95],[96]. The efficacy of ganciclovir still remains to be defined in 
controlled trials. Other early experience with treatment of intrauterine CMV infection using maternal oral 
administration of valaciclovir showed that it decreased the viral load in fetal blood significantly and could 
potentially also reduce the  morbidity of prolonged intrauterine infection [97]. The absence of adverse effects 
or teratogenecity of valaciclovir is compatible with its clinical use, but a well designed randomised controlled 
trial is needed. Currently, there is no approved vaccine for CMV, but two vaccines are in phase II studies: 
one is a recombinant vaccine containing the major envelope glycoprotein B of the virus with the adjuvant 
MF59 (gB/MF59) that induces high levels of neutralising antibodies, is safe and immunogenic in adults and 
infants, preventing also maternal CMV infection [98],[99]. The other vaccine is the live attenuated CMV 
Towne strain that stimulates neutralising antibodies comparable to those induced by wild type virus and 
protects renal transplant patients from severe CMV after  transplantation [93],[100]. 
The main interventions for the prevention of CMV infection should be aimed at women who wish to 
become pregnant, women who care for children and immunocompromised individuals. These individuals in 
whom exposure to CMV can be most detrimental will be the target groups for possible administration of a 
future vaccine [74]. 
From this study, rural residents had the higher CMV-IgG prevalence of 92%, while urban residents 
CMV –IgG seroprevalence was 90.9% (X2=0.169, P>0.05). The association between CMV-IgG 
seroprevalence  and residence was not confirmed by OR calculation (OR=0.872,P>0.05) which not agrees 
with the statement that low socio-economic status has been found as a strong risk factor for acquisition of 
CMV infection [101].  Our finding  was in agreement with that reported  recently for Kirkuk [53] and that 
reported for other geographical areas [72],[102]. 
In relation to educational status, CMV-IgG seroprevalence was significantly lower in uneducated 
(86.6%) as compared to educated women (92.8%) (X2=4.33, P=0.037).  OR confirm the association between 
CMV-IgG seroprevalence and educated women (OR=2.003, P=0.026). This finding was not in agreement to 
that reported for other countries [47,72][41,60] and recently reported for Kirkuk [53]. Illiteracy and low 
education levels were observed before as risk factors for increased susceptibility to acquisition of CMV 
infection, perhaps through the direct contact with contagious secretions from their own children and poor 
hygiene practiced by these women [101],[103]-[105].  
Likewise, low socioeconomic status has been found as a strong risk factor for acquisition CMV 
infection [101]. Nevertheless in Iraq it is difficult to investigate the socio-economic status of these pregnant 
women because the culture is based on generous hospitality attitude toward guest and family members who 
usually lives in extended families [53]. 
There was no difference in prevalence of CMV-IgG amongst working women (91.1%) as compared 
to housewife (91.2%) women. Using bivariate analyses, OR not confirmed a significant association between 
occupation and CMV-IgG seroprevalence. This finding agreed to that reported by others [53],[72]. In 
contrast, a reported study indicated that CMV-IgG seropositivity was more in housewife women occupation 
as compared to others [44].  
The present study shows a lower CMV-IgG seroprevalence in large size families (crowding index 
>3) (75.2%), than that in small size families (98.2%) (X2=73.4, P=0.000). OR confirmed the association 
between crowding index and CMV-IgG seropositivity (OR=17.713,P=<0.0001)  a finding not agreed to that 
reported by others [53],[104]. Housing crowdedness and family size are imperfect measures of the 
transmission dynamics that actually determine an individual’s risk of exposure [105]. No significant 
association was found between the prevalence of  BOH due to CMV infection and a mean household size of 
more than 3.0 persons.  Previous studies suggest a positive correlation of congenital CMV with a household 
size more than three persons and low socioeconomic status [87],[106]-[108].   
CMV IgM seroprevalence among women included in this study was 4.1% and vary significantly 
between pregnant (5.8%) and non pregnant (2.2%) women (X2=6.85, P=0.007). Although, CMV IgM 
seroprevalence was lower in women with bad obstetric history (3.8%) as compared to women with normal 
pregnancy (4.5%), but the difference was not significant. However,  current infection of 4.1%  and 7.2% 
seronegative in pregnant women represent a high rate of hazard for foetal infection. The current infection was 
lower (4.1%) than that reported recently (6.3%) for Kirkuk [53] indicating a decline in transmission of the 
virus in studied population.   
Globally reported CMV IgM seropositivity range was from 0% for Turkey [19]  to 13% for Poland 
[39] in pregnant women and from 0% for India [33] to 8.42% for India [13]. In Arab countries, the range of  
CMV IgM seropositivity was from 2.3% for Jordan [15] to 57.2 for Babylon, Iraq [14]  in pregnant women, 
while to range in women with BOH was from 1.4% for Jordan [15]  to 60.2% for Waset, Iraq [54]. Thus the 
present study finding for both women with normal pregnancy (4.5%) and with BOH (3.8%) lay within the 
reported ranges for global areas and for Arab countries. However, the current CMV  infection in our study 
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was lower to that reported for Waset [54], Babylon [14], Diwaniya [61], Mosul [109], Baghdad 
[55],[60],[110],  Al-Hila [56], Thi Qar [58,62] and Kirkuk [59],[53].   
CMV IgM seroprevalence varied by age (X2=0.88, P>0.05), with a highest rate of current infection 
(4.2%) in younger age (<30 yrs) as compared to elder (>30 yrs)(3.4%, X2=0.22, P>0.05). This finding agreed 
with previous studies which showed that elderly persons seem to be well protected against CMV infection 
due to accumulation of CD28 effector cytotoxic T lymphocytes [72]. This is a characteristic feature of all age 
groups but is most pronounced in elderly persons [111]. However, there is a lot of debate concerning 
maternal age and CMV infection; while many investigators observed that, elder women were at higher risk of 
CMV infection [72],[101], others reported the reverse [30] or absence of variation by age [78]. All of the 
above findings are consistent with the understanding that CMV IgM can be produced throughout life after 
primary infection or as a result of reinfection or reactivation [112],[13],  and suggest that in some older 
cohorts may be as likely to have a recurrent episodes as younger people are to have a primary infection [78].  
The present study finding indicated a significant differences in recent infections between control and 
women with BOH, who were with age of 20-29 (X2=4.43, P=0.03) and 30 – 39 (X2=7.3, P=0.007). this 
findings could be attributed to the age of marriage in Iraq (around 20 years) and sexual activity.  
Risk factors based on residence (OR=29.71,P=0.01), emerged for CMV IgM seroprevalence  in 
contrast to education, age, crowding index, occupation, smoking, haemoglobin level, animal exposure, 
number of abortion and congenital anomalies. Staras et al [79] not reported age as a risk for CMV IgM 
seropositivity, but confirmed the age as risk for CMV IgG seropositivity. The lack of identifiable risk factors 
for CMV IgM may be due to relatively low number of observations, and because over 80% of the IgM  
reactivity in tested sample was with high avidity and thus presumably from non primary CMV infection, 
which may be less associated with identifiable risk than primary infection [78]. In addition, a portion of  the 
IgM positive sera may have been false positive determinations known to occur with CMV IgM testing [114]. 
The current CMV infection was more predominant in urban women (5.6%;X2=10.18, P=0.000)), 
and this finding was agreed to that reported for Kirkuk [53] and  not consistent  with previously reported 
studies [72],[110],[115]. In addition, there was no significant differences in current CMV infection in regards 
to occupation, education, family size, smoking, haemoglobin level, number of abortion and congenital 
anomalies as OR was not significant. However, current infection was with significant differences between 
who exposed to animal and not exposed women (X2=8.99, P=0.001). Kolo et al [72] reported a high 
prevalence of  CMV IgM in pregnant women with primary education, which agrees with the reports from 
United States and Western Europe.  
The present study indicated a high CMV IgG seroprevalence (94.2%) in women with BOH who 
were smoking (X2=8.93, P=0.003) as  compared to non smoking (86.8%). OR confirmed that smoking was a 
risk factor for development of BOH in women infected previously with CMV. This could be explained on the 
basis that smoking may reactivate the latent CMV infection, a hypothesis that need a future research to 
confirm such association. Cigarette smoke was shown to augment the production of numerous 
proinflammatory cytokines and to decrease the levels of  anti-inflammatory cytokines [116]-[118]. In 
addition, smoking may play a role in the process of autoimmune disorders as reported in rheumatoid arthritis 
and systemic lupus erythematosus [117] , this phenomenon could be present in cases of abortion.  
Most of the reported studies have addressed the risk of spontaneous abortion in relation to smoking 
during pregnancy, however, results are not entirely consistent [119],[120]. The amount of daily smoking 
prior to pregnancy seems to be associated with an increased risk of spontaneous abortion, where as the 
duration of smoking does not seem to be related to an increased risk of spontaneous abortion [120]. The 
present study demonstrated a significant association between presence of CMV IgG positivity and smoking. 
Thus smoking could be a risk factor for CMV infection. However, this need to be evaluated in a study that 
take in consideration the amount of smoking.  
This study shows a higher (92.1%) CMV IgG seroprevalence in BOH women with haemoglobin 
level of <11 as compared to those with haemoglobin of >11(90.9%), but the difference was not significant 
(X2=0.06, P>0.05). OR not confirmed that iron deficiency anaemia as risk factor for BOH development in 
women infected with CMV. Anemia is a global public health problem. It has serious short- and long-term 
consequences during pregnancy and beyond. The anemic condition is often worsened by the presence of 
other chronic diseases . Untreated anemia also leads to increased morbidity and mortality from these chronic 
conditions as well [121]. In the present study we are not sure whether the anaemia was a consequence of the 
CMV  chronicity or the anaemia may be a risk factor for the development of CMV infection. This could be 
evaluated in a follow up study during pregnancy of a negative CMV pregnant.  
The exact mechanism by which anemia is caused in chronic inflammatory conditions is unknown. A 
common factor may be the contribution of hepcidin, a polypeptide hormone. Chronic inflammatory 
conditions lead to release of cytokines from the reticuloendothelial system as a part of cell-mediated 
immunity. In response to these cytokines, mainly interleukin 6 (IL-6) [122],[123], the liver produces 
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increased amounts of hepcidin, which in turn prevents release of iron from its stores. The process is mediated 
by blocking iron channels (such as ferroportin). Inflammatory cytokines also appear to influence other 
important aspects of iron metabolism, such as decreasing ferroportin expression, and possibly directly 
suppressing erythropoiesis by decreasing the ability of the bone marrow to respond to erythropoietin [124]. 
The present study indicated a higher (92.8%) CMV IgG seroprevalence in women exposed 
compared to those who not exposed (90.4%) to animals, however, the difference was not significant. There 
was no report present in the literature that described the association between animal exposure and CMV 
infection. While CMV is considered to be species specific, research group previously showed that baboon 
CMV can replicate on human fibroblasts in vitro [125].  The high positivity in exposed as compared to none 
exposed to animals may be due to presence of cross reactivity between HCMV and animal CMV. 
CMV IgG seroprevalence was significantly (X2=6.1, P=0.01) lower (89.5%) in women with 
frequent abortion (3-8) as compared to women (97.4%) non frequent abortion (1-2). OR confirmed the 
association between CMV IgG seroprevalence and number of abortion (OR=4.39, P=0.01). However, CMV 
IgG seroprevalence was higher (95.9%) in women with congenital anomalies pregnancy outcome as 
compared to those without (90.8%), but the difference not reach significant level (X2=.48, P>0.05). OR not 
confirmed as association between CMV IgG seroprevalence and development of congenital anomalies 
(OR=0.418, p>0.05).  
The high rate of CMV seroprevalence in women with low number of abortion may be a reflection of 
the high viraemia in primary infection. Then CMV antibodies waned with time so the seropositivity reduced 
and demonstrate a low seroprevalence of CMV IgG.    
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